RoundTable Healthcare Partners

Day-to-day investment decisions are made by a collective of Managing Partners that includes R. Craig Collister, Timothy J. Connors, Pierre Fréchette, Thomas P. Kapfer, and Barbara Sullivan. The two Founding Partners, Joseph F. Damico and Lester B. Knight, remain active as Senior Advisors. The firm operates a consensus-driven partnership model rather than a single-CIO structure.

RoundTable sources deals through decades-deep relationships with healthcare founders, family-owned companies, and large healthcare corporations shedding non-core divisions. The firm has built a specific capability around complex corporate carve-outs, supported by in-house operating partners who can stand up manufacturing, quality, and commercial functions independently. More than 90 add-on transactions across the portfolio demonstrate a repeatable pattern of buying and consolidating smaller assets around a platform.

RoundTable is a pure private equity fund manager, not a family office or a venture firm. It raises discrete, closed-end funds from institutional limited partners and invests exclusively in mature healthcare companies across control buyout, growth equity, and corporate carve-out transactions. It does not invest in seed- or early-stage companies.

RoundTable primarily makes direct control and minority equity investments into operating healthcare companies. The firm has not publicized a fund-of-funds or LP-commitment program, nor does it act as a passive investor in other private equity funds. All disclosed capital deployment runs through direct platform investments and add-on acquisitions.

The firm targets mature, revenue-generating healthcare businesses, entering through buyouts, corporate divestitures, public-to-private transactions, and growth-equity rounds in scaled companies. It does not invest in preclinical or clinical-stage biotech assets, revenue-less startups, or distressed/turnaround situations. The portfolio is concentrated in medical products, devices, generic and specialty pharmaceuticals, and branded consumer health.

RoundTable invests exclusively in healthcare, but notably avoids healthcare services segments like hospital systems, payer/provider models, and pure healthcare IT or software platforms. Its portfolio concentrates on tangible product categories — medical devices, disposables, branded and generic pharmaceuticals, consumer health, and select contract manufacturing — rather than asset-light service businesses.

There is no public evidence that RoundTable operates a foundation or a philanthropic vehicle tied to the firm or its funds. The firm separates its investing activity from any personal charitable activity of the partners; it does not market a double-bottom-line or impact-investing mandate.